Business
Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors
WESTLAKE VILLAGE, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"WESTLAKE VILLAGE, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Sue-Jean Lin has been appointed to the Arcutis Board of Directors effective June 9, 2021, and that Jonathan Silverstein, J.D. has decided to step down from the Board for personal reasons. “We thank Jonathan for his outstanding contributions to Arcutis,” commented Patrick Heron, Chairman of the Arcutis Board of Directors. “His leadership was instrumental in driving the continued success of the company over the past 4 years, including providing invaluable input to multiple successful private and public financings. We wish him all the best in his future endeavors, and we will deeply miss his intellect, humor and friendship.” “We are pleased to welcome Sue-Jean to the Arcutis Board,” said Frank Watanabe, Arcutis’ President and Chief Executive Officer. “She brings unique and very deep digital and information technology expertise to our board, as well as extensive executive experience in the life sciences industry. With 30 years of digital, operational, financial, and leadership experience in driving higher business performance for global pharmaceutical companies, Sue-Jean will play a critical role in guiding Arcutis as we expand and advance our pipeline of novel immuno-dermatology drug candidates and prepare for our first potential commercial launch.” “I am thrilled to join the Arcutis board at this pivotal time,” said Sue-Jean Lin. “The Company’s lead product candidate, topical roflumilast, shows strong promise as an innovative treatment for skin diseases where there is currently significant unmet need. I look forward to supporting the company’s growth trajectory with my insight and expertise, specifically in digital transformation, information technology, finance, risk management, and commercial operations.” Ms. Lin is Senior Vice President and Chief Information Officer at Alcon (NYSE: ALC), a global leader in eye care where she played a key role during its journey to becoming an independent, publicly traded company. Prior to Alcon, she was a member of the Hill-Rom executive leadership team, serving in the capacity of Se...